QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
| Professional Services Industry | Industrials Sector | Jon Pratt CEO | XFRA Exchange | NL0012169213 ISIN |
| NL Country | 5,500 Employees | 7 Jul 2026 Last Dividend | 8 Jan 2026 Last Split | 28 Jun 1996 IPO Date |
Founded in 1984 and headquartered in Venlo, the Netherlands, QIAGEN N.V. is a global leader in providing comprehensive solutions that convert biological materials into valuable molecular insights. The company’s innovative portfolio spans a wide range of sectors including molecular diagnostics, academia, pharmaceutical, and applied testing. QIAGEN is dedicated to facilitating the process of acquiring insights from biological samples through its extensive array of technologies and products, designed to support various stages of molecular analysis.